Table 3.
Use of integrative therapies (mistletoe therapy and hyperthermia) in n = 142 patients with advanced pancreatic cancer receiving chemotherapy.
| Integrative Therapies | Patients Receiving Chemotherapy (n = 142) | ||
|---|---|---|---|
| (A) Mistletoe therapy, n (%) | 117 (82.4) | ||
| Treatment initiation after first diagnosis (months), median (Q1;Q3) | 4.0 (1.5;12.3) | ||
| Treatment initiation after diagnosis of metastatic spread (months), median (Q1;Q3) | 1.9 (0.5;6.1) | ||
| Duration of therapy (days), median (Q1;Q3) | 41.0 (8.0;213.0) | ||
| (B) Hyperthermia therapy, n (%) | 74 (52.1) | ||
| Treatment initiation after first diagnosis (months), median (Q1;Q3) | 8.9 (3.9;13.8) | ||
| Treatment initiation after diagnosis of metastatic spread (months), median (Q1;Q3) | 5.7 (2.2;10.9) | ||
| Duration of therapy (days), median (Q1;Q3) | 57.0 (1.0;208.0) | ||
| Number of treatment sessions, median (Q1;Q3) | 4.0 (1.0;6.5) | ||
| Whole body hyperthermia, n (%) | 60 (81.1) | ||
| Local hyperthermia, n (%) | 26 (35.1) | ||
| Pancreas/epigastrium, n (%) | 22 (84.6) | ||
| Lung, n (%) | 1 (3.8) | ||
| Others, n (%) | 8 (30.8) | ||
Data are shown as numbers (percentage) or median (Q1;Q3). n, number.